Cerevance's Solengepras Hits Phase 3 Success for Parkinson's | Pharma and Biotech Daily

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of impactful advancements and strategic shifts shaping the industry landscape. Cerevance has made headlines with its drug Solengepras achieving a major milestone in a Phase 3 trial for Parkinson's disease. The drug significantly reduced "off" time, those challenging periods when symptoms resurface as medication effects diminish...